Trevena (TRVN) Competitors $1.76 -0.03 (-1.40%) (As of 12/20/2024 05:32 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRVN vs. IMCC, CANF, ELAB, PPBT, BMRA, AEZS, UPXI, BNOX, VRAX, and RNAZShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include IM Cannabis (IMCC), Can-Fite BioPharma (CANF), Elevai Labs (ELAB), Purple Biotech (PPBT), Biomerica (BMRA), Aeterna Zentaris (AEZS), Upexi (UPXI), Bionomics (BNOX), Virax Biolabs Group (VRAX), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry. Trevena vs. IM Cannabis Can-Fite BioPharma Elevai Labs Purple Biotech Biomerica Aeterna Zentaris Upexi Bionomics Virax Biolabs Group TransCode Therapeutics IM Cannabis (NASDAQ:IMCC) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Is IMCC or TRVN more profitable? Trevena has a net margin of 0.00% compared to IM Cannabis' net margin of -25.55%. Trevena's return on equity of 0.00% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets IM Cannabis-25.55% -129.86% -23.63% Trevena N/A N/A -119.55% Does the MarketBeat Community favor IMCC or TRVN? Trevena received 610 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 69.68% of users gave Trevena an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote. CompanyUnderperformOutperformIM CannabisOutperform Votes642.86% Underperform Votes857.14% TrevenaOutperform Votes61669.68% Underperform Votes26830.32% Which has preferable earnings and valuation, IMCC or TRVN? IM Cannabis has higher revenue and earnings than Trevena. IM Cannabis is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIM Cannabis$51.39M0.09-$7.04M-$3.41-0.61Trevena$443K3.43-$40.29M-$47.04-0.04 Do insiders & institutionals believe in IMCC or TRVN? 7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to IMCC or TRVN? In the previous week, Trevena had 2 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for Trevena and 0 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score. Company Overall Sentiment IM Cannabis Neutral Trevena Neutral Which has more risk and volatility, IMCC or TRVN? IM Cannabis has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Trevena has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Do analysts recommend IMCC or TRVN? Trevena has a consensus price target of $5.00, suggesting a potential upside of 184.09%. Given Trevena's stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryTrevena beats IM Cannabis on 11 of the 16 factors compared between the two stocks. Ad Porter & CompanyFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.52M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.0410.5589.7417.16Price / Sales3.43196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book-0.165.094.784.78Net Income-$40.29M$151.83M$120.31M$225.60M7 Day Performance18.92%-2.14%-1.92%-1.23%1 Month Performance4.76%-4.56%13.65%0.46%1 Year Performance-90.15%8.87%28.34%15.24% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena0.9412 of 5 stars$1.76-1.4%$5.00+184.1%-89.8%$1.52M$443,000.00-0.0440Analyst ForecastGap UpIMCCIM Cannabis0.0458 of 5 stars$2.38-3.6%N/A+3.4%$5.31M$51.39M-0.72340Gap DownCANFCan-Fite BioPharma1.7928 of 5 stars$1.50-5.1%$14.00+833.4%-30.7%$5.31M$667,000.00-0.888ELABElevai Labs0.3443 of 5 stars$2.04-10.9%N/A-99.3%$5.28M$2.45M-0.0318News CoverageGap DownPPBTPurple Biotech1.6721 of 5 stars$3.93+2.6%$33.00+739.7%N/A$5.23MN/A-0.4720BMRABiomerica0.142 of 5 stars$0.31-1.2%N/A-76.8%$5.22M$5.51M-0.8260Gap DownAEZSAeterna ZentarisN/A$2.90flatN/A-68.1%$5.20M$2.37M-0.2020Analyst ForecastUPXIUpexi2.3432 of 5 stars$4.84-1.2%$25.00+416.5%-79.2%$5.05M$83.98M0.00130Earnings ReportPositive NewsGap DownBNOXBionomics2.5163 of 5 stars$0.29-11.8%$8.00+2,707.0%-81.3%$5.03M$10,000.000.00N/AVRAXVirax Biolabs Group0.6842 of 5 stars$1.52-3.2%N/A+25.0%$4.91M$84,872.000.005News CoverageRNAZTransCode Therapeutics2.9565 of 5 stars$6.67-10.1%$99.00+1,384.3%-99.9%$4.67MN/A0.009Analyst ForecastAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies IMCC Alternatives CANF Alternatives ELAB Alternatives PPBT Alternatives BMRA Alternatives AEZS Alternatives UPXI Alternatives BNOX Alternatives VRAX Alternatives RNAZ Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRVN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
